MARKET

SNTI

SNTI

Senti Bioscience
NASDAQ
0.7718
-0.0183
-2.32%
After Hours: 0.8090 +0.0372 +4.82% 19:18 03/30 EDT
OPEN
0.7800
PREV CLOSE
0.7901
HIGH
0.8188
LOW
0.7701
VOLUME
176.01K
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
0.7702
MARKET CAP
24.04M
P/E (TTM)
-0.2760
1D
5D
1M
3M
1Y
5Y
1D
Senti Biosciences Is Maintained at Buy by Chardan Capital
Dow Jones · 18h ago
Senti Biosciences Price Target Cut to $11.00/Share From $13.00 by Chardan Capital
Dow Jones · 18h ago
Chardan Capital Maintains Buy on Senti Biosciences, Lowers Price Target to $11
Benzinga · 18h ago
Weekly Report: what happened at SNTI last week (0323-0327)?
Weekly Report · 21h ago
Buy Rating on SENTI-202 Driven by Strong Early AML Efficacy and De-Risking Regulatory Designations Despite Financing Overhang
TipRanks · 3d ago
Senti Bio reports Q4 EPS (53c), consensus (47c)
TipRanks · 3d ago
Senti Biosciences Q4 EPS $(0.53) Misses $(0.48) Estimate, Sales $22.000K Miss $666.667K Estimate
Benzinga · 3d ago
Senti Biosciences Q4 revenue misses analyst estimates
Reuters · 3d ago
More
About SNTI
Senti Biosciences, Inc. and its subsidiaries is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The Company is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.

Webull offers Senti Biosciences, Inc stock information, including NASDAQ: SNTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNTI stock methods without spending real money on the virtual paper trading platform.